Many broadly neutralizing antibodies (bnAbs) targeting the HIV-1 envelope glycoprotein are
being assessed in clinical trials as strategies for HIV-1 prevention, treatment, and …

Pre-exposure prophylaxis (PrEP) is a pivotal intervention among HIV prevention strategies.
We aimed to narratively revise the topic of HIV acute infection in the setting of PrEP …

Host restriction factors play key roles in innate antiviral defense, but it remains poorly
understood which of them restricts HIV-1 in vivo. Here, we used single-cell transcriptomic …

The incubation period, or the time from infection to symptom onset, of COVID-19 has usually
been estimated by using data collected through interviews with cases and their contacts …

Toll-like receptor 7 (TLR7) agonist and PGT121 (broadly neutralizing antibody, bnAb)
administration previously delayed viral rebound and induced SHIV remission. We evaluated …

Previously, we showed that substitution of HIV-1 envelope (Env) residue 375-Ser by bulky
aromatic residues enhances binding to rhesus CD4 and enables primary HIV-1 Envs to …

Background Among people living with HIV, elite controllers (ECs) maintain an undetectable
viral load, even without receiving anti-HIV therapy. In non-EC patients, this therapy leads to …

Determining which immunological mechanisms contribute to the development of broad
neutralizing antibodies (bNAbs) during HIV-1 infection is a major goal to inform vaccine …

Background Multiple waves of the COVID-19 epidemic have hit most countries by the end of
2021. Most of those waves are caused by emergence and importation of new variants. To …

Pathogen diversity resulting in quasispecies can enable persistence and adaptation to host
defenses and therapies. However, accurate quasispecies characterization can be impeded …